Abstract
An algorithm for use of Prasugrel (Effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention at the Brigham and Women's Hospital is presented. Our algorithm, which is in the process of being implemented, is consistent with published and generally accepted standards of care and is based on data from the pivotal Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38, which compared clopidogrel with prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Areas of focus include analysis of the benefit of prasugrel over clopidogrel in acute coronary syndrome patients and appropriate selection of patients for prasugrel treatment.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angioplasty, Balloon, Coronary*
-
Cardiac Catheterization*
-
Clinical Protocols
-
Clinical Trials as Topic
-
Clopidogrel
-
Comparative Effectiveness Research
-
Guidelines as Topic
-
Hemorrhage / chemically induced*
-
Humans
-
Myocardial Infarction / physiopathology
-
Myocardial Infarction / therapy*
-
Patient Care Planning
-
Piperazines* / administration & dosage
-
Piperazines* / adverse effects
-
Prasugrel Hydrochloride
-
Purinergic P2Y Receptor Antagonists / administration & dosage
-
Purinergic P2Y Receptor Antagonists / adverse effects
-
Risk Assessment
-
Standard of Care
-
Thiophenes* / administration & dosage
-
Thiophenes* / adverse effects
-
Thrombolytic Therapy / adverse effects
-
Thrombolytic Therapy / methods
-
Ticlopidine / administration & dosage
-
Ticlopidine / adverse effects
-
Ticlopidine / analogs & derivatives*
-
Treatment Outcome
Substances
-
Piperazines
-
Purinergic P2Y Receptor Antagonists
-
Thiophenes
-
Clopidogrel
-
Prasugrel Hydrochloride
-
Ticlopidine